Biochina

Biochina company information, Employees & Contact Information

Explore related pages

Related company profiles:

BIOCHINA, organized by EnmoreBIO, is the largest bio convention in China, covering the full ecosystem in Chinese bio industry. By associating with the scientific research, biotech and biopharma, government regulation agencies, and clinical institutions, CDMOs, CROs, the convention lined up each sectors aims to advance the bio ecosystem in China. BIOCHINA2025 featured five major professional exhibition halls, 850 speakers, 204 forums, and served 30378 attendees,with over 500 international delegates from 28 countrie. Building on the BIOCHINA project, we also run online media channels in China, and webinars internationally. With a sustained impact throughout the year, BIOCHINA offers a continuous series of events and resources, including: • BIOCHINA Global Forum @ Seoul | September 12 • BPD2025 @ Singapore | September 24–26 • BIOCHINA 2026 | Suzhou, China | March 12–14 Here for the post report of BIOCHINA 2025: https://static.biocn.cn/file/BIOCHINA2025_PostEvent_Report.pdf BIOCHINA 2025 Magazine : https://static.biocn.cn/file/BIOCHINA2025_Magazine.pdf
Looking for a particular Biochina employee's phone or email?

Biochina Questions

News

BIOCHINA2026 – Fusion Forward: Uniting The Global Biopharma Community In Suzhou - Bioprocess Online

BIOCHINA2026 – Fusion Forward: Uniting The Global Biopharma Community In Suzhou Bioprocess Online

Biocon launches first US manufacturing facility in Cranbury, NJ - Investment Monitor

Biocon launches first US manufacturing facility in Cranbury, NJ Investment Monitor

Biocon eyes generic Wegovy obesity drug launch in India, Canada in next 2 years, CEO says - Reuters

Biocon eyes generic Wegovy obesity drug launch in India, Canada in next 2 years, CEO says Reuters

Biocon founder Shaw harming Bengaluru’s interests with her social media posts, says Karnataka Dy CM Shivak - The Economic Times

Biocon founder Shaw harming Bengaluru’s interests with her social media posts, says Karnataka Dy CM Shivak The Economic Times

Biocon inks settlement, license pact with Amgen to market biosimilars in US - Business Standard

Biocon inks settlement, license pact with Amgen to market biosimilars in US Business Standard

Biocon Foundation Begins Construction of New School Building in Kodamballi to Support 250 Students - TheCSRUniverse

Biocon Foundation Begins Construction of New School Building in Kodamballi to Support 250 Students TheCSRUniverse

Biocon sees mid-teens revenue growth on biosimilars, generics push - Mint

Biocon sees mid-teens revenue growth on biosimilars, generics push Mint

Biocon Foundation supports Government High School, kicks off construction of new building for 250 students - Express Pharma

Biocon Foundation supports Government High School, kicks off construction of new building for 250 students Express Pharma

Biocon’s Rs 4,500 crore QIP to help retire debt, fuel new launches, says CEO Sidharth Mittal - Moneycontrol

Biocon’s Rs 4,500 crore QIP to help retire debt, fuel new launches, says CEO Sidharth Mittal Moneycontrol

Biocon Foundation Builds New School for 250 Students - Construction World India

Biocon Foundation Builds New School for 250 Students Construction World India

India's Biocon urges government to exempt cancer, rare-disease drugs from tax in budget - Reuters

India's Biocon urges government to exempt cancer, rare-disease drugs from tax in budget Reuters

Biocon gets regulatory nod for GLP-1 diabetes drug Liraglutide in India - CNBC TV18

Biocon gets regulatory nod for GLP-1 diabetes drug Liraglutide in India CNBC TV18

Biocon inaugurates first manufacturing facility in US - The Economic Times

Biocon inaugurates first manufacturing facility in US The Economic Times

Biocon eyes early lead in generic Wegovy, Ozempic sales in Canada from 2026 - Business Standard

Biocon eyes early lead in generic Wegovy, Ozempic sales in Canada from 2026 Business Standard

Biocon Biologics and Civica, Inc. Collaborate to Expand Insulin Aspart Access in the United States - PR Newswire

Biocon Biologics and Civica, Inc. Collaborate to Expand Insulin Aspart Access in the United States PR Newswire

Biocon Inaugurates First US Manufacturing Facility in Cranbury - New Jersey Business Magazine

Biocon Inaugurates First US Manufacturing Facility in Cranbury New Jersey Business Magazine

FDA Approves Biocon Biologics' Bevacizumab Biosimilar - Center for Biosimilars

FDA Approves Biocon Biologics' Bevacizumab Biosimilar Center for Biosimilars

Biocon eyes generic semaglutide market for 2026 - Endpoints News

Biocon eyes generic semaglutide market for 2026 Endpoints News

Biocon Q4 net profit surges 153%, biosimilars, generics drive growth - Moneycontrol

Biocon Q4 net profit surges 153%, biosimilars, generics drive growth Moneycontrol

Biocon Biologics Announces U.S. FDA Approval for Jobevne™, Biosimilar Bevacizumab, Expanding Its Oncology Portfolio - PR Newswire

Biocon Biologics Announces U.S. FDA Approval for Jobevne™, Biosimilar Bevacizumab, Expanding Its Oncology Portfolio PR Newswire

India-based Biocon opens first U.S. manufacturing facility in Cranbury - ROI-NJ

India-based Biocon opens first U.S. manufacturing facility in Cranbury ROI-NJ

Biocon Biologics Expands Diabetes Portfolio with FDA Approval of Kirsty™, the First and Only Interchangeable Rapid-Acting Insulin Aspart in the United States - GlobeNewswire

Biocon Biologics Expands Diabetes Portfolio with FDA Approval of Kirsty™, the First and Only Interchangeable Rapid-Acting Insulin Aspart in the United States GlobeNewswire

Biocon accused of committing IP theft to create cancer biotech Bicara - Fierce Biotech

Biocon accused of committing IP theft to create cancer biotech Bicara Fierce Biotech

FDA rejects Biocon insulin biosimilar over data, manufacturing concerns - Fierce Pharma

FDA rejects Biocon insulin biosimilar over data, manufacturing concerns Fierce Pharma

BOARD OF DIRECTORS - Biocon

BOARD OF DIRECTORS Biocon

India's Biocon developing its own version of Wegovy, clinical trial likely next year - Reuters

India's Biocon developing its own version of Wegovy, clinical trial likely next year Reuters

BIOCHINA 2025: China’s Largest Bio Convention to Host Over 3,000 Biotech Companies - BioSpectrum Asia

BIOCHINA 2025: China’s Largest Bio Convention to Host Over 3,000 Biotech Companies BioSpectrum Asia

Biocon continues to divest with $150M sale of insulin and other brands to Eris - Fierce Pharma

Biocon continues to divest with $150M sale of insulin and other brands to Eris Fierce Pharma

After Five Years of Successful Experience Internationally, Biocon Biologics’ Hulio® Biosimilar to Humira®, Now Available in the United States - Biocon

After Five Years of Successful Experience Internationally, Biocon Biologics’ Hulio® Biosimilar to Humira®, Now Available in the United States Biocon

Investors - Biocon

Investors Biocon

FDA slaps Biocon following inspections of biosimilar production sites in India, Malaysia - Fierce Pharma

FDA slaps Biocon following inspections of biosimilar production sites in India, Malaysia Fierce Pharma

Viatris unloads biosimilar business to partner Biocon for $3.3B - Fierce Pharma

Viatris unloads biosimilar business to partner Biocon for $3.3B Fierce Pharma

Our work in Biosimilars - Biocon

Our work in Biosimilars Biocon

Biocon opens first US manufacturing facility: Kiran Mazumdar-Shaw confirms FDA approval — Here's all we know - Mint

Biocon opens first US manufacturing facility: Kiran Mazumdar-Shaw confirms FDA approval — Here's all we know Mint

Biocon Founder Visits DK Shivakumar Amid Face-Off Over Bengaluru Infra - NDTV

Biocon Founder Visits DK Shivakumar Amid Face-Off Over Bengaluru Infra NDTV

Biocon Malaysia - Asia’s largest insulin manufacturing and R&D facility - Biocon

Biocon Malaysia - Asia’s largest insulin manufacturing and R&D facility Biocon

Legacy - Biocon - Global Biopharmaceutical company - Biocon

Legacy - Biocon - Global Biopharmaceutical company Biocon

Biocon Biologics Completes Acquisition of Viatris’ Global Biosimilars Business - Biocon

Biocon Biologics Completes Acquisition of Viatris’ Global Biosimilars Business Biocon

MANUFACTURING OPERATIONS - Biocon

MANUFACTURING OPERATIONS Biocon

KEY MANAGEMENT TEAM - Biocon

KEY MANAGEMENT TEAM Biocon

Biocon Q4FY25 Revenue at Rs 4,454 Cr, Up 15%** EBITDA at Rs 1,115 Cr; Up 16%; Net Profit at Rs 344 Cr, Up 153% - Biocon

Biocon Q4FY25 Revenue at Rs 4,454 Cr, Up 15%** EBITDA at Rs 1,115 Cr; Up 16%; Net Profit at Rs 344 Cr, Up 153% Biocon

BOARD OF DIRECTORS - Biocon

BOARD OF DIRECTORS Biocon

Functions - Biocon - Global Biopharmaceutical company - Biocon

Functions - Biocon - Global Biopharmaceutical company Biocon

Biocon Biologics posts strong Q1 growth as North America, Europe deliver | Company Business News - Mint

Biocon Biologics posts strong Q1 growth as North America, Europe deliver | Company Business News Mint

Biocon opens first US manufacturing plant in New Jersey - BusinessLine

Biocon opens first US manufacturing plant in New Jersey BusinessLine

Profit margins, US medicine supplies may get hit: Biocon - Times of India

Profit margins, US medicine supplies may get hit: Biocon Times of India

Biocon Biologics Receives USD 150 Million Capital Injection from Goldman Sachs - Biocon

Biocon Biologics Receives USD 150 Million Capital Injection from Goldman Sachs Biocon

I live in Karnataka, not Maharashtra, Biocon's Kiran Mazumdar-Shaw hits back at Congress leader - The Economic Times

I live in Karnataka, not Maharashtra, Biocon's Kiran Mazumdar-Shaw hits back at Congress leader The Economic Times

Is Biocon making a comeback? - Finshots

Is Biocon making a comeback? Finshots

Biocon Foundation - Real progress impacts everyone - Biocon

Biocon Foundation - Real progress impacts everyone Biocon

Biocon revenue grows 15%, profit dips sharply - Mint

Biocon revenue grows 15%, profit dips sharply Mint

Biocon gets USFDA's tentative approval for antibacterial drug Rifaximin - Business Standard

Biocon gets USFDA's tentative approval for antibacterial drug Rifaximin Business Standard

Here's why Biocon shares were trading higher on the bourses on October 20 - Business Standard

Here's why Biocon shares were trading higher on the bourses on October 20 Business Standard

FDA gives Biocon biosimilars plant clean bill of health - Fierce Pharma

FDA gives Biocon biosimilars plant clean bill of health Fierce Pharma

A Century of Insulins - Biocon - Global Biopharmaceutical company - Biocon

A Century of Insulins - Biocon - Global Biopharmaceutical company Biocon

Is Now The Time To Put Biocon (NSE:BIOCON) On Your Watchlist? - simplywall.st

Is Now The Time To Put Biocon (NSE:BIOCON) On Your Watchlist? simplywall.st

Biocon to sell stake in biosimilar arm and Syngene: Sources - The Economic Times

Biocon to sell stake in biosimilar arm and Syngene: Sources The Economic Times

Minister: Biocon Failed Human Insulin Supply Contractual Obligations - CodeBlue

Minister: Biocon Failed Human Insulin Supply Contractual Obligations CodeBlue

Biocon Biologics marks one year as global biosimilars enterprise - Business Standard

Biocon Biologics marks one year as global biosimilars enterprise Business Standard

Biocon Q1 results: Net profit down 95%, revenue rises 15% to ₹4,022 cr - Business Standard

Biocon Q1 results: Net profit down 95%, revenue rises 15% to ₹4,022 cr Business Standard

Biocon Biologics refinances $1.1 bn debt through bonds, syndicated facility - Business Standard

Biocon Biologics refinances $1.1 bn debt through bonds, syndicated facility Business Standard

Biocon Biologics partners Malaysia’s top cancer NGO for affordable cancer drugs - financialexpress.com

Biocon Biologics partners Malaysia’s top cancer NGO for affordable cancer drugs financialexpress.com

Biocon shares in focus as it opens manufacturing facility in New Jersey - Business Today

Biocon shares in focus as it opens manufacturing facility in New Jersey Business Today

Will launch 3 biosimilars globally in 2-3 years: Biocon Biologics CEO & MD - Business Standard

Will launch 3 biosimilars globally in 2-3 years: Biocon Biologics CEO & MD Business Standard

Eris buys India formulation biz of Biocon Biologics for Rs 1,242 crore - Business Standard

Eris buys India formulation biz of Biocon Biologics for Rs 1,242 crore Business Standard

Decision on merger with Biocon Biologics soon, says Siddharth Mittal - Business Standard

Decision on merger with Biocon Biologics soon, says Siddharth Mittal Business Standard

BIOCON Stock Price and Chart — NSE:BIOCON - TradingView

BIOCON Stock Price and Chart — NSE:BIOCON TradingView

Biocon Share Price Today - Biocon Stock Price Live NSE/BSE - ICICI Direct

Biocon Share Price Today - Biocon Stock Price Live NSE/BSE ICICI Direct

Biocon India Group - MIT Sloan

Biocon India Group MIT Sloan

Biocon Ltd Share Price Today, BIOCON Share Price NSE, BSE - Business Today

Biocon Ltd Share Price Today, BIOCON Share Price NSE, BSE Business Today

Biocon Share Price Target 2025, 2026, 2030, 2050 - shareprice-target.com

Biocon Share Price Target 2025, 2026, 2030, 2050 shareprice-target.com

Top Biochina Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant